Fairmount Funds Management LLC
Follow13F filer, CIK 1802528, WEST CONSHOHOCKEN, PA
Fairmount Funds Management LLC reported $1,594,519,847 across 12 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 97.54% of the portfolio.
Accepted , ingested 13F-HR 0001104659-26-128188
- Period
- 2026-09-30
- Reported value
- $1.59B
- Holdings
- 12
- Top 10 weight
- 97.54%
- New
- 2
- Sold out
- 2
Stakes and trades reported after 2026-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- MTRI MENTARI THERAPEUTICS INC: 13D 10,555,507 shares, 19.99% of the class, 13D filed 2026-11-12, 0001193125-26-458677Timeline
Accepted , ingested - TCRT ALAUNOS THERAPEUTICS INC: 13D 858,789 shares, 19.99% of the class, 13D filed 2026-10-15, 0001683168-26-007898Timeline
Accepted , ingested - SYRE SPYRE THERAPEUTICS INC: 13D/A 10,185,961 shares, 9.99% of the class, 13D/A filed 2026-10-09, 0001104659-26-115087Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| KRSAnew | +9,103,729 | $291M |
| DMRAnew | +8,713,000 | $185M |
| CBIOadded | +853,450 | $12.5M |
| ZBIOadded | +12,333 | $333K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| DMRAexited | -8,713,000 | -$227M |
| APGEexited | -298,647 | -$39.6M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001104659-26-128188, largest first. % of portfolio is the value over $1,594,519,847, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| ORKAORUKA THERAPEUTICS INC | 3,705,262 | $309M | 19.35% | 0 | Timeline | ||
| KRSAKORSANA BIOSCIENCES INC | 9,103,729 | $291M | 18.27% | new | Timeline | ||
| DNTHDIANTHUS THERAPEUTICS INC | 2,537,191 | $223M | 14.01% | 0 | Timeline | ||
| DMRADAMORA THERAPEUTICS INC | 8,713,000 | $185M | 11.63% | new | Timeline | ||
| COGTCOGENT BIOSCIENCES INC | 5,503,418 | $176M | 11.05% | 0 | Timeline | ||
| VRDNVIRIDIAN THERAPEUTICS INC | 5,090,928 | $105M | 6.57% | 0 | Timeline | ||
| ELVNENLIVEN THERAPEUTICS INC | 1,855,644 | $85.1M | 5.33% | 0 | Timeline | ||
| JBIOJADE BIOSCIENCES INC | 4,553,494 | $64M | 4.01% | 0 | Timeline | ||
| ZBIOZENAS BIOPHARMA INC | 2,371,358 | $64M | 4.01% | +12,333 | Timeline | ||
| CBIOCRESCENT BIOPHARMA INC. | 3,601,316 | $52.5M | 3.3% | +853,450 | Timeline | ||
| FTHFAETH THERAPEUTICS INC | 722,020 | $21.5M | 1.35% | 0 | Timeline | ||
| IKTINHIBIKASE THERAPEUTICS INC | 8,625,000 | $17.7M | 1.11% | 0 | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001104659-26-128188 | base | 2026-11-16 |